RSS
10 Mar 2021

Lannett Development Of Biosimilar Insulin Glargine Product Continues To Advance

Author: admintech | Filed under: Press Release

PHILADELPHIA, March 10, 2021 /PRNewswire/ — Lannett Company, Inc. (NYSE: LCI) today announced that it recently received feedback from the U.S. Food and Drug Administration (FDA) regarding biosimilar insulin glargine, a product the company is co-developing with its strategic alliance…

This entry was posted on Wednesday, March 10th, 2021 at 7:12 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

«

»